TERENCE JOHN CAMPBELL AM
Date of Birth: 9th December, 1949
Address: University Department of Medicine, St Vincent’s Hospital, Darlinghurst, Sydney, 2010
1972 Bachelor of Science (Medicine) 1st Class Honours, University of New South Wales
1975 Bachelor of Medicine, Bachelor of Surgery, 1st Class Honours, University of NSW
1981 Fellow of the Royal Australasian College of Physicians
1983 Doctor of Philosophy, University of Oxford
1990 Fellow, American College of Cardiology
1991 Fellow, European Society of Cardiology
1991 Doctor of Medicine, University of NSW
1994 Fellow, Council on Clinical Cardiology, American Heart Association
1998- Professor of Medicine, University of New South Wales and
Head – University Department of Medicine, St Vincent’s Hospital, Sydney
2003- Deputy Director, Victor Chang Cardiac Research Institute
2004- 6 Associate Dean (Research), Faculty of Medicine, UNSW
2006- Senior Associate Dean, Faculty of Medicine, UNSW
1975-77 Intern and Resident Medical Officer, St. Vincent's Hospital
1978-80 Cardiology Registrar, St. Vincent's Hospital
1980-82 Nuffield Dominions Demonstrator, University Department of Pharmacology, Oxford,
England; also Honorary Senior Registrar (1980-81), and Honorary Clinical
Assistant (1982), Department of Cardiovascular Medicine, John Radcliffe Hospital,
CV - T. Campbell 1
1983-84 Cardiology Research Fellow, Honorary Deputy Director, Coronary Care Unit, St.
1984-85 National Health and Medical Research Council Senior Research Officer, School of
Medicine, University of NSW
1985-86 Lecturer, School of Physiology & Pharmacology, University of NSW
July 1986 Promoted to Senior Lecturer with tenure
Aug 1987 Appointed Senior Lecturer in Medicine (conjoint) at St. Vincent's Hospital
1990-93 Chairman, Department of Cardiology, St. Vincent's Hospital
1990-98 Senior Staff Specialist in Clinical Pharmacology and Cardiology, St. Vincent's
Deputy Director, Dept. of Clinical Pharmacology, St. Vincent's Hospital
Director, Coronary Care Unit, St. Vincent's Hospital
Associate Professor (Conjoint), Schools of Medicine, and of Physiology &
1995- Faculty Member, Victor Chang Cardiac Research Institute
Staff Association Prize for Proficiency in the Clinical Years of the Medical Course 1975
Shared prize for Psychiatry on Graduation 1975
Awarded Membership of the Order of Australia (AM), 2003
MEMBERSHIP OF SOCIETIES
1978-86 Associate Member, Cardiac Society of Australia and New Zealand
1986- Cardiac Society of Australia and New Zealand
-Honorary Secretary 1991-96
1985- Australian Physiological and Pharmacological Society
2001 Australian Society for Medical Research
1990- American College of Cardiology (Fellow)
1992-Australian Society for Clinical & Experimental Pharmacology and Toxicology
1994- American Heart Association (International Fellow)
1995- International Society of Cardiovascular Pharmacotherapy
1995- Heart Rhythm Society (North America)
CV - T. Campbell 2
St. Vincent’s Hospital/University of NSW:
1990- Drug Committee, St. Vincent's Hospital (Deputy Chairman, 1992-2002; Chairman
1990-93 Chairman, Dept of Cardiology, St. Vincent's Hospital (Rotating 3 year position)
1990-93 Medical Board Executive, St. Vincent's Hospital (elected representative of Division of
1992- Special Access Scheme for Unmarketed Drugs - Delegate for St. Vincent's
1994- Research Ethics Committee, St. Vincent's Hospital (Chairman 1996-8)
1996- Management Committee, St Vincent's Clinical Trials Centre
1996-2000 Cardiopulmonary Resuscitation Committee
1998- Member, Campus Medical Council, St. Vincent’s Hospital
1999- Member, Board of St. Vincent’s Clinic
1999- Member, Medical Staff Appointments & Credentials Committee, St. Vincent’s Hospital
(Chairman from 2001).
1999-Member, Research Committee, Faculty of Medicine, UNSW
2001- Chairman, Patient Safety Committee, St Vincent’s Hospital
1986 – 2003 Scientific Subcommittee, Cardiac Society of Australia and New Zealand.
1989- Member, NHMRC Regional Grants Interviewing Committees (Adelaide, 1989;
Adelaide/Perth 1991; Melbourne 1992;
1991-9 Education Committee, National Heart Foundation (NSW); Chairman from 1996
1991-96 Specialist Advisory Committee (Cardiology), Royal Australasian College of
1992- Specialist Registry of Overseas Referees, Hong Kong Research Grants
1994- Subcommittee on Cardiovascular diseases, Australian Clinical Casemix
CV - T. Campbell 3
1995- Therapeutics Advisory Committee, Royal Australasian College of Physicians
(Chairman from 1996)
1995-8 Maintenance of Professional Standards Committee, RACP
1995-2002 Specialties Board, RACP
1995-6 Chairman, Pharmaceuticals and Devices Committee, Cardiac Society, ANZ
1996-9 University of NSW Human Ethics Committee
1996-2008 Member, Board of NSW Division of National Heart Foundation (Deputy President
2002-6 Member National Board, National Heart Foundation of Australia
2007- Member, Scientific Advisory Committee, 45 and Up Study
1992-98 Member, Australian Drug Evaluation Committee (ADEC)
1995-96 NSW Health Department Ad Hoc Committee on Guidelines for Cardiac
1996-97 Member, Reference Committee for Review of Therapeutic Goods Administration
1997-98 Member, Advisory Committee, National Prescribing Service, Dept. Health & Family
Services (Representing RACP).
1997.8Member Education Advisory Committee for Therapeutic Group Premiums initiative of
Government (Representing RACP)
2001- Member, Pharmaceutical Benefits Advisory Committee (PBAC).
2003 Member, Expert Committee on Complementary Medicines in the Health System
2004 Co-Chair, Govt Cttee to review Statin prescribing in Australia
EDITORIAL BOARDS, REFEREEING, ETC
Regular Referee for:- Medical Journal of Australia, Circulation, Circulation Research, The Journal
of Molecular and Cellular Cardiology, The European Journal of Pharmacology, the British Journal
of Pharmacology, and Cardiovascular Drugs & Therapy
CV - T. Campbell 4
Editorial Board, "Modern Medicine" of Australia, "Heart", U.K., and J Cardiovasc Pharmacol Ther.,
CURRENT RESEARCH INTERESTS - LABORATORY
Current Research staff :
Dr Jamie Vandenberg NHMRC R D Wright Fellow
Dr Cath Clarke Post-doctoral Fellow
Dr Jing Ting Zhao Post-doctoral Fellow
Dr Adam Hill Post-doctoral Fellow
Ken Wyse, BSc Research Assistant
Jane Bursill, BTC Technical Officer
i) Proarrhythmic Effects of Cardioactive Agents
These studies use the same model as outlined in (i) above, as well as the transfected mammalian cell
line models outline below. Essentially we are studying the ability of drugs used as antiarrhythmic
agents, as well as some antihistamines, antipsychotic agents, antidepressants etc which are known to
occasionally provoke tachyarrhythmias.
ii) Studies of Isolated Human Potassium Channels
These comprise the largest part of our current work. We use transfected ion channels- both stable
transfections into mammalian cell lines and transient transfections into Xenopus oocytes. We are
studying a number of questions to do with the structure-function relationships of various channels,
including gating mechanisms and drug-binding properties where relevant. Channels under study
include “HERG” the drug-sensitive delayed rectifier cardiac potassium channel and others.
iii) Studies of a Novel Chloride Channel (NCC27)
This work is in collaboration with Prof Sam Breit at St Vincents, and also being carried out by Drs
Tonini and Mazzanti from Milan. It involves the electrophysiological characterisation of a novel protein
cloned by Dr Breit in the Centre for Immunology which codes for a chloride channel which is
preferentially expressed on the nuclear membrane rather on the plasma membrane. We are studying
this transfected into CHO- K1 cells, and nuclear membranes .
PEER-REVIEWED EXTERNAL RESEARCH SUPPORT
Year Source Title Amount ($)
1980 Nuffield Nuffield Dominions Demonstratorship 13,000
CV - T. Campbell 5
1981 Dominions 15,000
1982 Scheme, U.K. 20,000
1984 NHMRC Mechanisms of action of Class I 48,818
1985 “ antiarrhythmic drugs 45,185
1986 NHMRC Electrophysiologic effects of Class I 27,577
1987 " antiarrhythmic drugs on heart cells 24,108
1988 " 24,508
1986 Ramaciotti Class I antiarrhythmic drug effects on sinus node 12,300
1988 NHF Patch clamp study of Class I antiarrhythmic drug 15,000
1989 Ramaciotti Antiarrhythmic drug effects on isolated human 15,142
1990 NHMRC Antiarrhythmic drug action in simulated ischaemia 31,500
1991 " 32,500
1992 " 34,000
1990 NHF Arrhythmogenic effects of antiarrhythmic drugs 36,083
1991 " in canine Purkinje fibres 39,617
1992 " 43,312
1992 NHF Patch-clamp study of ion channels in cardiac 61,000
1993 " myocytes 68,700
1993 NHF Arrhythmogenic effects of cardioactive drugs 33,829
1994 " 39,223
1993 Ramaciotti Patch-clamp study of ion channels in vascular 15,000
smooth muscle cells
1992-3 CRC CRC for Cardiac Technology 18,000
1994 NHMRC Antiarrhythmic drug action in simulated 50,054
1995 " ischaemia 50,054
1996 " 50,054
1995 NHF Cellular effects of antiarrhythmic drugs 38,925
1996 " 38,925
1995-96 NHF Scholarship (P West) 44,000
1997-99 NHF Scholarsip (C. Singleton) 66,000
1997-99 NHMRC Scholarship (B Walker) 66,000
1997 NHMRC Modulation of antiarrhythmic 51,905
1998 " " Drug action by ischaemia 52,804
1999 " " and tachycardia 52,804
1998 NHF Electrophysiology & pharmacology of the 49,500
1999 human transient outward potassium current 51,000
1998 Ramaciotti Studies of potassium channels in human cardiac
CV - T. Campbell 6
1998-2000 NHMRC Scholarship (H. Tie) 66,000
1999-2001 ARC A mathematical and experimental analysis of 173,900
2000 Ramaciotti Ion channels in the pathogenesis and treatment of
cardiac, vascular and inflammatory diseases 18,000
2000–2001 NHF Electrophysiology and pharmacology of the
human cardiac potassium channel, HERG 99,000
2000–2002 NHMRC The human cardiac transient outward potassium
channel Kv4.3: A study of its pharmacology and
modulation by disease states 196,254
2001-2003 NHMRC Structure function relationship of ncc27, a
novel nuclear chloride ion channel protein 240,000
2002-4 NHMRC HERG K+ channels:Molecular basis of gating 435,000
2002-4 NHMRC Transition of NCC27 (CLIC1) chloride ion channels 300,000
from the soluble to the membrane bound form
2002-3 NHF The molecular basis of refractoriness in the heart 97,576
2004-6 NHMRC The in vivo and in vitro biology of the novel
intracellular ion channel CLIC1 (NCC27) 425,250
2004-6 NHMRC NHMRC Scholarship (Subbiah) 80,000
2005-7 NHMRC Molecular basis of voltage-dependent activation 432,750
of HERG K+ channels
2005-7 ARC Characterisation of two pore domain potassium 277,000
channels: structure function studies of the
M1-P1 loops of TASK channels. Clarke,
Vandenberg, Campbell, Torres, Mathie
2007-9 NHMRC The feasibility and impact of cardiovascular 799,346
absolute risk assessment in general practice .
Harris, Zwar, Campbell et al
PEER-REVIEWED INTERNAL SUPPORT
Year Source Title Amount ($)
1983 St. Vincent's Hospital Research Fellowship 16,000
1983 " Research Grant 10,000
1983 " (MPU) Research Grant (Equipment) 20,000
1993 " Antiarrhythmic drug action in simulated 25,000
1993 St. Vincent's Clinic Intracellular control mechanisms for ion 7,338
channels in smooth muscle
CV - T. Campbell 7
1994 St. Vincent's Hospital Inhibition of potassium channels by 20,000
1994 St. Vincent's Clinic Effectiveness of antiarrhythmic drugs 24,885
1995 St. Vincent's Hospital Cardiac ATP-sensitive potassium channels 12,000
1995 St. Vincent's Clinic Role of ion channels in vascular endothelial
cell biology 33,000
1996 St. Vincent's Clinic Drug actions on cardiac potassium channels 20,000
1997 St Vincent's Clinic Differential proarrhythmic actions 20,000
of antidepressant drugs
2000 St Vincents Clinic Possible role for potassium channels in heart 80,000
2003 St Vincents Clinic Structure of the HERG K channel binding site 20,000
2004 St Vincents Clinic Binding to HERG K channels 20,000
2007 St Vincents Clinic Protein trafficking defects as a cause of congenital
long QT syndrome 25,000
2008 St Vincents Clinic The state dependence of drug binding to the 100,000
human ether-a-go-go-related gene K+ channel
INDUSTRY-SPONSORED RESEARCH FUNDING
Year Source Title Amount ($)
1988 E. R. Squibb Basic study of captopril 2,000
1988 Reckitt & Colman Study of amiodarone 1,000
1992 Boehringer-Ingelheim Zatebradine Trial 10,000
1993 " " 10,000
1992 Eli Lilly Unspecified 5,000
1993 Winthrop Laboratories "CAPRIE" Trial 15,000
1993 Boehringer - Ingelheim "GUSTO" Trial 12,104
1994 Boehringer - Ingelheim Zatebradine Trial 7,417
1994 Boehringer - Ingelheim "GUSTO" Trial 2,430
1994 Sanofi-Winthrop "CAPRIE" Trial 39,300
1994 Bristol-Myers Squibb "SWORD" Trial 7,022
1994 Pfizer Dofetilide Trial 7,000
1994 Bristol-Myers Squibb "LIPID" Trial 3,960
1995 Winthrop CAPRIE 17,050
CV - T. Campbell 8
INVITED LECTURES & SEMINARS
1986 Co-chairman of a session on anti-arrhythmic drugs at International Society for Heart
Research Annual Scientific Meeting, Melbourne
1987 Invited speaker and co-ordinator of Symposium entitled "Anti-Arrhythmic Drugs", held as part
of Tenth International Congress of Pharmacology, Sydney, August 1987
1988 Invited speaker in Symposium entitled "The Role of Membranes in Regulating Muscle
Contraction", held as part of Bicentennial Meeting of Australasian Physiological &
Pharmacological Society, A.N.U. February 1988
1988 Invited lecture on: "New insights into the mechanisms of action of antiarrhythmic drugs at the
level of the cell membrane": In a Symposium on "New Developments in Antiarrhythmic Drugs"
at the Bicentennial Meeting of the Cardiac Society of Australia & New Zealand & the Royal
Australasian College of Physicians, Sydney, 8 May 1988
1988 Invited to present a poster at International Conference on Molecular & Cellular Mechanisms
of Antiarrhythmic Agents, Nashville, USA
1989 Invited by Japanese Circulation Society to give a lecture on the Clinical Relevance of the
Subclassification of Class I Antiarrhythmic drugs at a Satellite Symposium of their Annual
Scientific Meeting, Nagoya, March 1989, and to speak at a scientific meeting in Tokyo during
the same visit
1992 Invited Speaker, Cardiac Society, Satellite Meeting, Melbourne
1994 Invited Speaker, Saudi Heart Association Annual Scientific Sessions, Saudi Arabia
1994 Invited Chairman, International Society of Hypertension, Satellite Meeting on Heart Failure,
1994 Invited Speaker, 24th Annual Scientific Session, Republic of China Society of Cardiology,
Taipei, May 1st
1995 Invited Speaker, (3 Seminars) Cardiac Society Annual Scientific Meeting, Canberra
1996 Invited Speaker and Chair (2 sessions) International Society of Cardiovascular
Pharmacotherapy Meeting, Sydney, February
1996 Invited Speaker, North American Congress of Clinical Toxicology, Portland, Oregon - October
1996 Invited Speaker, University of Oregon, Medical Center Grand Rounds, Emergency
Department - October 15
1996 Invited Speaker, Hennepin County Medical Center, Medical Grand Rounds - October 16
1997 Invited Speaker, Asian Pacific Symposium on Pacing and Electrophysiology, Delhi, India, -
2003 Invited Chairman, North American Society of Pacing & Electrophysiology
2001 Invited speaker, International Cardiology meeting, Beijing
CV - T. Campbell 10
2002 Invited speaker, Great Wall of China Cardiology meeting, Beijing
2003 Invited Chair, American College of Cardiology, Annual scientific Sessions, Chicago
2003 Invited speaker Cardiac Society of ANZ Annual Scientific meeting
2004Invited Speaker and Chair of Symposium at World congress of Clinical Pharmacology and
toxicology, Brisbane, August 5
2006 Invited speaker Cardiac Society of ANZ Annual Scientific meeting
2006 Invited speaker-Symposium World Congress of Cardiology, Barcelona, Sept 2006
Undergraduate Medical and Science Students
Twenty five years of extensive experience in lecturing and tutoring on campus in Physiology,
Pharmacology and at St Vincents Hospital in Therapeutics and small group tutorials for Clinical
Research Student Supervision (As primary supervisor)
Present Mark Perrin MB BS (PhD student about to enrol)
1986 Regan Pallandi, BSc (Hons)
1988 Paul Hemsworth, BSc (Hons)
1990-93 Victor Ye, MSc (Awarded 1993)
1994-96 Paul West M.D. (Awarded 1998)
1997.2000 Bruce Walker PhD (Awarded 2000)
1997.2001 Cameron Singleton, M.D (Awarded 2002)
1998-2002 Hui Tie, MD (Awarded 2003)
2000.2003 Suresh Singarayar MD (Awarded 2004)
2002-5 Raj Subbiah MB,BS, PhD Student (awarded 2005)
Chairman, Cardiology Department, St. Vincent's Hospital, 1990-93 (three-year, rotating
Director, Coronary Care Unit, St. Vincent's Hospital, 1990-8
Deputy Director, Clinical Pharmacology Department, St. Vincent's Hospital, 1990-
CV - T. Campbell 11
Honorary Secretary, Cardiac Society of Australia & New Zealand, 1991-96
President, Cardiac Society of Australia & New Zealand, 2000-2.
Chairman, Pharmaceuticals and Devices Committee, Cardiac Society, ANZ, 1995-96
Chairman, Research Ethics Committee St. Vincent's Hospital, 1996 –99.
Chairman, Education Committee NSW Division of National Heart Foundation, 1996-9.
Chairman, Therapeutics Advisory Committee RACP, 1996-2001.
Chair, Patient safety Cttee, St Vincents Hospital 2002-6
Chair, Education Cttee, St Vincents Hospital, 1998-
Chair, Medical Staff Appointments and Credentials Cttee, St Vincents, 2000-
Head of School, St Vincents Clinical School 2000-
Associate Dean(Research), Faculty of Medicine 2004-
CV - T. Campbell 12
FULL PAPERS IN PEER-REVIEWED JOURNALS OR BOOKS
As at August 2007: Total citations=1993 (incl 144 self-citations); h-index=20 with 4 papers
having>100 citations [Details saved on separate version of my papers]
1. Campbell T and Heath,T. Intrinsic contractility of lymphatics in sheep and in dogs. Quart J Expr
Physiol 1973; 58: 207-17.
2. Hugh TB and Campbell TJ. Contact cholangiography. Am J Surgery 1976; 132: 562-4.
3. Campbell TJ, Hickie JB, Michell G and O'Rourke MF. Nifedipine in the treatment of life
threatening Prinzmetal angina. Aust NZ J Med 1979; 9: 293-4.
4. Campbell TJ and Morgan JJ. Treatment of atrial arrhythmias after cardiac surgery with
intravenous disopyramide. Aust NZ J Med 1980; 10: 644-9.
5. O'Rourke MF, Norris RN, Campbell TJ, Chang VP and Sammel NL. Randomized controlled trial
of intra-aortic balloon counterpulsation in early myocardial infarction with acute heart failure. Am J
Cardiol 1981; 47: 815-20.
6. Campbell TJ and Vaughan Williams EM. Electrophysiological and other effects on rabbit hearts of
CCI 22277, a new steroidal antiarrhythmic drug. Br J Pharmacol 1982; 76: 337-34.
7. Vaughan Williams EM, Millar JS and Campbell TJ. Electrophysiological effects of labetolol on
rabbit atrial, ventricular and Purkinje cells in normoxia and hypoxia. Cardiovasc Res 1982; 16:
8. Vaughan Williams EM and Campbell TJ. The effects of nadolol on various cardiac tissues in
normoxia and on atrial muscle in simulated ischaemia. Eur J Pharmacol 1982; 83: 161-9
9. Campbell TJ. Voltage-and time-dependent depression of maximum rate of depolarisation of
guinea-pig ventricular action potentials by two steroidal anti-arrhythmic drugs, CCI 22277 and Org
6001. Br J Pharmacol 1982; 77: 541-8.
10. Campbell TJ. Studies on the mode of action of cardioactive drugs in animals and man. DPhil
Thesis, Oxford University, 1982.
11. Campbell TJ.and Vaughan Williams EM. Voltage-and time -dependent depression of maximum
rate of depolarisation of guinea-pig ventricular action potentials of two new anti-arrhythmic drugs,
flecainide and lorcainide. Cardiovasc Res 1983; 17: 251-8
12. Campbell TJ. Resting and rate-dependent depression of maximum rate of depolarisation (Vmax)
in guinea-pig ventricular action potentials by mexiletine, disopyramide and encainide. J
Cardiovasc Pharmacol 1983; 5: 291-6.
13. Campbell TJ. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are
important in determining their effects on refractoriness in guinea-pig ventricle, and provide a
theoretical basis for their subclassification. Cardiovasc Res 1983; 17: 344-52.
14. Campbell TJ. Importance of physico-chemical properties in determining the kinetics of the effects
of Class I antiarrhythmic drugs on maximum rate of depolarisation in the guinea-pig ventricle. Br
J Pharmacol 1983; 80: 33-40.
CV - T. Campbell 13
15. Campbell TJ. Antiarrhythmic agents. Med J Aust 1984; 141: 718-23.
16. Gavaghan TP, Feneley MP, Campbell TJ and Morgan JJ. Atrial tachyarrhythmias after cardiac
surgery: results of disopyramide therapy. Aust NZ J Med 1985; 15: 27-32.
17. Campbell TJ, Gavaghan TP and Morgan JJ. Intravenous sotalol for treatment of atrial fibrillation
and flutter after cardiopulmonary bypass: comparison with disopyramide and digoxin in a
randomized trial. Br Heart J 1985; 54: 86-90.
18. Gavaghan TP, Kelly RP, Kuchar DL, Hickie JB and Campbell TJ. The prevalence of arrhythmias
in hypertrophic cardiomyopathy: role of ambulatory monitoring and signal-averaged
electrocardiography. Aust NZ J Med 1986; 16: 666-670.
19. Kuchar DL, Campbell TJ and O'Rourke MF. Long term survival after counterpulsation for
medically refractory heart failure complicating myocardial infarction and cardiac surgery. Eur
Heart J 1987; 8: 490-502.
20. Campbell TJ. Cellular electrophysiological effects of d- and dl -sotalol in guinea-pig sinoatrial
node, atrium and ventricle and in human atrium. Br J Pharmacol 1987; 90: 593-599.
21. Campbell TJ. Differing electrophysiological effects of Class IA, IB and IC antiarrhythmic drugs on
guinea-pig sinoatrial node. Br J Pharmacol 1987; 91: 395-401.
22 Pallandi RT, Perry MA and Campbell TJ. Proarrhythmic effects of an oxygen-derived free radical
generating system on action potentials recorded from guinea-pig ventricular myocardium: a
possible cause of reperfusion induced arrhythmias. Circ Res 1987; 61: 50-54.
23. Pallandi RT and Campbell TJ. Resting, and rate-dependent depression of V max of guinea-pig
ventricular action potentials by amiodarone and desethylamiodarone. Br J Pharmacol 1987; 92:
24. Campbell TJ. A possible role for free radicals in cardiac reperfusion phenomena. (Editorial). Aust
NZ J Med 1987; 17: 459-460.
25. Pallandi RT and Campbell TJ. Selective depression of conduction of premature action potentials
in canine Purkinje fibres by class IB antiarrhythmic drugs: Comparison with IA and IC drugs.
Cardiovasc Res 1988; 22: 171-178.
26. Gavaghan TP, Keogh AM, Kelly RP, Campbell TJ, Thorburn C and Morgan JJ. Flecainide versus
digoxin/disopyramide for acute atrial tachyarrhythmias after cardiopulmonary bypass. Br Heart J
1988; 60: 497-501.
27. Vaughan Williams EM and Campbell TJ (Eds). Handbook of Experimental Pharmacology.
Volume: Antiarrhythmic Drugs, Springer-Verlag, Berlin, 1989.
28. Campbell TJ. Subclassification of antiarrhythmic drugs. In: Handbook of Experimental
Pharmacology. Volume: Antiarrhythmic Drugs; E, Vaughan Williams & TJ Campbell (Eds).
Springer-Verlag, Berlin, 1989: 135-155.
29. Campbell TJ. Pharmacology of Class Ia Agents. In: Handbook of Experimental Pharmacology,
Volume: Antiarrhythmic Drugs; EM Vaughan Williams & TJ Campbell (Eds), Springer-Verlag,
Berlin, 1989: 175-199.
30. Campbell TJ. Clinical Efficacy for Arrhythmias of Cardiac Glycosides. In: Handbook of
Experimental Pharmacology, Volume: Antiarrhythmic Drugs; EM Vaughan Williams & TJ
Campbell (Eds), Springer-Verlag, Berlin, 1989: 565-568.
CV - T. Campbell 14
31. Campbell TJ. Characteristics of cardiac action potentials in marsupials. J Comp Physiol B 1989;
32. Hemsworth PD and Campbell TJ. Resting and rate-dependent depression of maximum rate of
depolarization of guinea-pig ventricular action potentials by metabolites of encainide. Br J
Pharmacol 1989; 97: 619-625.
33. Hemsworth PD, Pallandi RT and Campbell TJ. Cardiac electrophysiological actions of captopril:
lack of direct antiarrhythmic actions. Br J Pharmacol 1989; 98: 192-196.
34. Campbell TJ. Antiarrhythmic Drugs. In: Eckert GM, Gutmann F & Keyser H (Eds):
Electropharmacology, C.R.C. Press, Florida, 1990: 247-268.
35. Campbell TJ. Antiarrhythmic drugs - mechanisms of action. Aust Prescr 1990; 13: 15-19.
36. Campbell TJ, Hemsworth PD. Selective depression of maximum rate of depolarisation of guinea-
pig ventricular action potentials by amiodarone and lignocaine in simulated ischaemia:
Comparison with encainide. Clin Exp Pharmacol Physiol 1990; 17: 135-145.
37. Campbell TJ. Pro-arrhythmic action of antiarrhythmic drugs: A review. Aust NZ J Med 1990; 20:
38. Campbell TJ, Wyse KR and Hemsworth PD. Effects of hyperkalemia, acidosis and hypoxia on the
depression of maximum rate of depolarization by Class I antiarrhythmic agents in guinea-pig
myocardium: differential actions of Ib and Ic agents. J Cardiovasc Pharmacol 1991; 18: 51-59.
39. Campbell TJ, Wyse KR and Pallandi R. Differential effects on action potential duration of Class
Ia, Ib and Ic antiarrhythmic drugs: modulation by stimulation rate and extracellular K
concentration. Clin Exp Pharm Physiol 1991; 18: 533-541.
40. Campbell TJ. Treatment of atrial fibrillation: Time for change? Med J Aust 1992; 157: 78-80.
41. Campbell TJ. Recent developments in the pharmacotherapy of cardiac failure. Med J Aust 1992;
42. Campbell TJ. Subclassification of Class I antiarrhythmic drugs: Enhanced relevance after CAST.
Cardiovasc Drugs Ther 1992; 6: 519-528.
43. Ye V, Wyse KR and Campbell TJ. Lidocaine shows greater selective depression of myocardium in
simulated ischemia than propafenone: Possible implications for proarrhythmia. J Cardiovasc
Pharmacol 1993; 21: 47-55.
44. Wyse KR, Ye V and Campbell TJ. Action potential prolongation exhibits simple dose
-dependence for sotalol, but reverse dose-dependence for quinidine and disopyramide:
Implications for proarrhythmia due to triggered activity. J Cardiovasc Pharmacol 1993; 21:
45. Campbell TJ. Sodium channel blockers. In: Singh BN, Dzau VJ, Vanhoutte PM and Woosley RL
(Eds); Cardiovascular Pharmacology and Therapeutics, Churchill Livingstone, New York. 1994;
Chapter 41: 645-663.
46. Wyse KR, Ye V and Campbell TJ. Effects of hyperkalaemia on the depression of maximum rate
of depolarization by Class I antiarrhythmic agents in guinea-pig myocardium. Br J Pharmacol
1993; 108: 255-261.
CV - T. Campbell 15
47. Campbell TJ. Antiarrhythmic drugs. Med J Aust 1994; 160: 202-205.
48. Campbell TJ. Class III antiarrhythmic action: The way forward? Med J Aust 1993; 158: 732-733.
49. Campbell TJ. Digitalis for patients with heart failure in sinus rhythm? Med J Aust 1993; 159:
50. Martin DK, Nakaya Y, Wyse KR and Campbell TJ. Effects of disopyramide and flecainide on the
kinetics of inward rectifier potassium channels in rabbit heart muscle. Br J Pharmacol 1994; 111:
51. Bursill JA, Wyse KR and Campbell TJ. Quinidine but not disopyramide prolongs cardiac Purkinje
fiber action potentials following a pause. J Cardiovasc Pharmacol 1994; 23: 833-837.
52. Campbell TJ. Antiarrhythmic drug therapy: Future directions. J Saudi Heart Assoc 1994; 6:
53. Campbell TJ. Treatment of atrial fibrillation. Aust Family Physician 1994; 23: 924-933.
54. Nakaya, Y. Martin, D.K. Campbell, T.J. Effect of E-4031, Sotalol and MS-551 on single inward-
rectifier potassium channels in rabbit heart cells. Jpn. Heart J. 1996; 35 (Supp.1) 275-276.
55 Martin DK, Nakaya Y, Wyse KR, Bursill JA, West PD, Campbell TJ. Inhibition of ATP-sensitive
potassium channels in cardiac myocytes by a novel antiarrhythmic agent, MS-551. Pharmacol.
Toxicol. 1995; 77: 65-70
56. Martin DK, Bootcov MR, Campbell TJ, French PW, Breit SN. Human macrophages contain a
stretch-sensitive potassium channel that is activated by adherence and cytokines. J Membrane
Biol 1995; 147: 305-315
57. Campbell TJ. Proarrhythmia: Cellular mechanisms. J Saudi Heart Assoc 1996; 8: 10-20.
58. West P.D., Bursill J.A., Wyse K.R., Martin D.K., Campbell T.J. Effect of the class III
antiarrhythmic agent E-4031 on the ATP sensitive potassium channel in rabbit ventricular
myocytes. Pharmacol.Toxicol. 78, 89-93, 1996.
59. Pallandi R.T., Lovell N.J., Campbell T.J. Class III antiarrhythmic effects of dofetilide in rabbit atrial
myocardium. J.Cardiovasc.Pharmacol.Therapeut. 1996; 1: 229-234.
60 Campbell T.J. Proarrhythmic complications of sotalol (Invited Editorial). Aust NZ J Med 1996;
61. Campbell, T.J. Is this Arrhythmia Significant? Aust Family Physician 1996; 25: 1045-1050.
62. Campbell, T.J Beta-Blockers for ventricular arrhythmia: Have we underestimated their value?
Aust. N.Z.J. Med. 1996; 26: 689-696.
63. West P.D. Bursill J.A. Wyse K.R. Martin D.K. Campbell T.J. (1996). Effect of dofetilide and D-
sotalol on the ATP-sensitive potassium channel of rabbit ventricular myocytes. J. Cardiovasc.
Pharmacol. Therapeut. 1996; 1: 307-312.
64. Wyse K.R, Bursill J.A, and Campbell T.J. Differential effects of antiarrhythmic agents on post pause
repolarisation in cardiac Purkinje fibres. Clin Exp Pharm Phys 1996; 23: 825-829.
65. Martin, D.K. Boneham, G.C. Pirie, B.L. Collin, H.B. & Campbell, T.J. Chloride ion channels are
associated with adherence of lymphatic endothelial cells. Microvasc. Res. 1996; 52: 200-209.
CV - T. Campbell 16
66. Campbell T.J. Antiarrhythmic Drugs. In: Thompson,P.(Ed) - Manual of Coronary Care, Churchill
Livingstone, London, 1997; pp. 225-244.
67. Nakaya, Y. Martin, D.K. Campbell, T.J. The novel class III antiarrhythmic agent MS-551 blocks
the cardiac inward rectifier with greater potency than sotalol or E-4031: possible relevance to
reverse use-dependence. J.Cardiovasc. Pharm Therapeut. 1997; 2: 39-46
68. Firkin, F. Campbell, T. Safety of chloramphenicol eye drops. Aust.N.Z.J. Ophthal. 1997; 25: 3.
69. Campbell, T.J. Anticoagulation for atrial fibrillation. Mod. Medicine, 1997; 40: 34 - 38
70. Valenzuela,S.M. Martin,D.K .Por,S.B. Robbins,J.M. Bootcov,M.R. Schofield,P.R. Campbell, T.J.
Breit,S.N. Molecular cloning and expression of a chloride ion channel of cell nuclei.
J.Biol.Chem. 1997; 272: 12575-12582.
71. Campbell, T.J. Antiarrhythmic Drugs in: Principles of Medical Biology, Vol. 8B: Molecular and
Cellular Pharmacology, Bittar E.E. (ed). JAI Press Greenwich, CT, USA 1997. pp 519 - 527
72. West, P.D. Martin, D.K. Bursill, J.A. Wyse, K.R. Campbell, T.J. Modulation of the
electrophysiologic actions of E-4031 and dofetilide by hyperkalemia and acidosis in rabbit
ventricular myocytes. J.Cardiovasc.Pharmacol.Ther. 1997; 2: 205-212
73. Campbell, T.J. The place of amiodarone: an overview of the four recent large amiodarone trials.
A.N.Z. J.Med.27, 1997; 582-590.
74. West PD, Martin DK, Bursill JA, Wyse KR, Campbell TJ. Comparative study of the effects of
erythromycin and roxithromycin on action potential duration and potassium currents in canine
Purkinje fibers and rabbit myocardium. J Cardiovasc Pharmacol. Therapeut.3;. 1998; 29-36.
75. Campbell TJ and Williams KM. Therapeutic Drug Monitoring: Antiarrhythmic Drugs. Br J Clin
Pharmacol; 1998; 46: 307-319.
76. Day RO, Chalmers DRC, Williams KM, Campbell TJ. The death of a healthy volunteer in a human
research project:implications for Australian clinical research. Med J Aust; 1998; 168: 449-451.
77. Martin D, Bursill J, Qui M, Breit SN and Campbell T. Alternative hypothesis for efficacy of
macrolides in acute coronary syndromes. The Lancet, 1998; 351,1858-1859.
78. Campbell TJ, Pentel PR, Straka RJ, Swanson AL and Parra D, Antiarrhythmic Drug Poisoning;
In:"Intensive Care Medicine" R.S. Irwin, F.B. Cerra, and J.M Rippe, (eds.), Lippincott-Raven,
Boston, 1999; pp 1494-1511.
79. Walker BD, Valenzuela SM, Singleton CB, Tie H, Bursill JA, Wyse KR, Qiu MR, Breit SN,
Campbell TJ. Inhibition of HERG channels stably expressed in a mammalian cell line by the
antianginal agent perhexiline maleate. Brit J Pharmacol 1999; 127(1): 243-251.
80. Singleton CB, Valenzuela SM, Walker BD, Tie H, Wyse KR, Bursill JA, Qui MR, Breit SN,
Campbell TJ. Blockade by N-3 polyunsaturated fatty acid of the Kv4.3 current stably expressed
in Chinese Hamster ovary cells. Brit J Pharmacol 1999, 127:941-948.
81. Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela S, Qiu MR, Breit SN and Campbell
TJ. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride:
affinity for inactivated state. Brit J Pharmacol 1999, 128; 444-450.
82. Singleton CB, Walker BD, Campbell TJ. N-3 polyunsaturated fatty acids and cardiac mortality.
Aust NZ J Med 2000; 30(2): 246-251.
CV - T. Campbell 17
83. Tie, H, Walker BD, Valenzuela SM, Breit SN, Campbell TJ. The heart of psychotropic drug
therapy. (Letter) Lancet 2000; 355: 1824-1825.
84. Tonini R, Ferroni A, Valenzuela S, Warton K, Campbell TJ, Breit SN, Mazzanti M.
Characterisation of the NCC27 nuclear protein in stable transfected. FASEB J 2000; 14:
85. Tie H, Walker BD, Singleton CB, Valenzuela SM, Bursill JA, Wyse KR, Breit SN, Campbell TJ.
Inhibition of HERG potassium channels by the antimalarial agent halofantrine. Br J Pharmacol
2000; 140: 1967-75.
86. Campbell T, Harper W. Guidelines for unstable angina: evidence-based medicine in the
information age (Editorial). Med. J. Aust. 2000; 173: 399-400.
87. Walker BD, Singleton CB, Tie H, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, Campbell TJ.
Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene
(HERG) potassium channel. Cardiovasc Res 2000; 48: 44-58.
88. Valenzuela SM, Mazzanti M, Tonini R, Qiu MR, Warton K, Musgrove EA, Campbell TJ, Breit SN.
The nuclear chloride ion channel NCC27 is involved in regulation of the cell cycle. J Physiol .
2000. 529: 541-551.
89. Campbell TJ. Update on the use of magnesium as an antiarrhythmic drug. Cardiac
Electrophysiology Review 2000. 4: 251-254.
90. Tie H, Walker BD, Singleton CB, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, Campbell TJ.
Clozapine and sudden death. J Clin Psychopharmacol, 2001; 21: 630-632.
91. Vandenberg JI, Walker, BD, Campbell TJ. HERG K+ channels: friend and foe, Trends Pharmacol.
Sci., 2001: 22; 240-246.
92. Baumann A.E. and Campbell, T.J. Heart week 2001: “Get active” a call to action. Med J. Aust.
2001; 174: 381-382.
93 Harrop, S.J., DeMaere,M.Z., Fairlie, W.D., Reztsova,T. Valenzuela, S.M. Mazzanti, M. Tonini, R.
Qiu, M.R. Jankova, L. Warton, K. Bauskin,A.R., Wu, W.M. Pankhurst,S., Campbell, T.J. Breit,
S.N., Curmi, P.M.G. Resolution of the Soluble Form of the Intracellular Chloride Ion Channel
CLIC1 (NCC27). Crystal Structure at 1.4Ã J Biol Chem 2001; 276: 44993-45000.
94. Singarayar S, Singleton C, Tie H, Wyse K, Bursill J, Bauskin A, Wu W, Valenzuela S, Breit S,
Campbell TJ. Components of Ischaemia and Kv4.3 Currents, J. Mol. Cell Cardiol 2002;34:
95. Warton,K., Tonini,R., Fairlie,W.D., Matthews,J.M., Valenzuela,S.M., Qiu,M.R., Wu,W.M., Susan
Pankhurst,S., Bauskin,A.R., Harrop,S.J., Campbell,T.J., Curmi,P.M.G., Breit,S.N., Mazzanti,M.
Recombinant CLIC1 (NCC27) assembles in lipid bilayers via a pH-dependent two-state process to
form chloride ion channels with identical characteristics to those observed in CHO cells expressing
CLIC1. J.Biol.Chem.2002, 277: 26003-26011.
96. Qiu MR, Campbell TJ, and Breit SN.. A potassium ion channel is involved in
cytokine production by activated human macrophages. Clin Exp Immunol., 2002; 130; 67-74.
97. Singarayar, S. Bursill, J. Wyse, K. Bauskin, A. Wu, W. Vandenberg, J. Breit, S. Campbell, T.
2003. Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine.
J. Cardiovasc. Electrophysiol. 2003; 14: 641-650.
CV - T. Campbell 18
98. Campbell, T.J. and Macdonald, P.S. Digoxin in heart failure. Med. J. Aust. 179 (2): 98-102,
99. Vandenberg, JI, Torres, AM, Campbell, TJ, Kuchel, PW. The HERGK + channel: Progress in
understanding the molecular basis of its unusual gating kinetics. Europ J. Biophys. 33: 89-97;
2004 (Epub ahead of print-Sept 10, 2003).
100.Torres, A, Bansal , PS, Sunde, M, Clarke, C, Bursill, JA, Smith, DJ, Bauskin, A, Breit, SN,
Campbell, TJ, Alewood, P, Kuchell, PW, Vandenberg, JI. Structure of the HERG K+ channel S5P
extracellular linker: Role of an amphipathic α-helix in C-type inactivation. J. Biol.Chem. 2003; 278,
101. Littler, D R, Harrop, SJ, Fairlie WD, Brown, LJ, Pankhurst, GJ, DeMaere, MZ, Campbell, TJ,
Bauskin, AR, Tonini, R, Mazzanti, M, Breit, SN, Curmi, PM. The intracellular chloride ion channel
protein CLIC1 undergoes a redox-controlled structural transition. J.Biol.Chem.2004
102. Subbiah, RN, Clarke, CE, Smith, DJ, Zhao, JT, Campbell, TJ, and Vandenberg, JI. Molecular
basis of slow activation of Human ether-a-go-go related gene (HERG) potassium channel. J.
Physiol. 2004; 558 (Part 2), 417-431.
103.Subbiah, RN, Campbell, TJ, Vandenberg, JIV. Inherited cardiac arrhythmia syndromes: What
have they taught us about arrhythmias and anti-arrhythmic therapy? Clin Exp Pharm Physiol
2004; 31: 906-912
104.Thompson, PL, Meredith, I, Amarena, J, Campbell, TJ, Sloman, JG, and Harris, PJ for the
PACT Investigators. Effect of pravastatin compared with placebo initiated within 24 hours of the
onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary
Treatment (PACT) Trial. Am. Heart J. 2004 148; e2-e8.
105.Kovacic, JC, Horton, MDA, Campbell, TJ, and Wilson, SL. Left atrial hematoma complicating
inferior myocardial infarction. J Am Soc Echocardiography 2004; 17, 1201-3.
106.Subbiah,R N, Kondo,M, Campbell,TJ and Vandenberg, JI, Tryptophan scanning mutagenesis
of the HERG K+ channel:The S4 domain is loosely packed and likely to be lipid exposed. J
Physiol 2005; 569:367-379.
107.Campbell, T.J. Amiodarone Australian Prescriber 2005; 28: 150-154.
108.Clarke, C E, Hill, AP, Zhao, JT, Kondo, M, Subbiah, RN, Campbell, TJ and Vandenberg, JI
Effect of S5P and alpha-helix charge mutants on inactivation of hERG K+ channels” J Physiol
2006; 573: 291-304.
109.Hill, A.P., Sunde, M., Campbell, T.J., Vandenberg, J.I. Mechanism of block of the hERG K+
channel by the scorpion toxin CnErg1. Biophys J 2007 92; 3915-29.
110.Hill, A.P., Campbell, T.J. Bansal P., Kuchel P. and Vandenberg J.I. The S631A mutation
causes a mechanistic switch in the block of hERG channels by CnErg1. Biophys J 2007 (In press)
CV - T. Campbell 19
FULL PEER –REVIEWED PUBLICATIONS ARISING FROM MULTICENTRE TRIALS IN WHICH
DR CAMPBELL ACTED AS LOCAL CO-ORDINATOR
1. The GUSTO Investigators. An international randomized trial comparing four thrombolytic
strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
2. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24
hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-766.
3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in
suspected acute myocardial infarction: collaborative overview of mortality and major morbidity
results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
4. ISIS-4 Collaborative Group: ISIS-4: A randomised factorial trial assessing early oral captopril, oral
mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute
myocardial infarction. Lancet 1995; 345, 669-685.
5. Design features and baseline characteristics of the LIPID (Long-term Intervention with Pravastatin
in Ischemic Disease) Study - Am J Cardiol 1995; 76: 474-479
6. Effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent or remote
myocardial infarction. Waldo AL, Camm AJ, de Ruyter H, et al for the SWORD Investigators.
Lancet 348, 7-12, 1996.
7. The GUSTO llb Investigators. A comparison of recombinant hirudin with heparin for the treatment
of acute coronary syndromes. N. Engl. J. Med. 335, 775-782, 1996
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients
at risk of ischemic events. Lancet 1996; 348: 1329-1339.
9. The PARAGON Investigators. International,randomized,controlled trial of lamifiban (a platelet
glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation, 97, 2386-95, 1998.
10. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in
patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med,
339, 1349-1357, 1998.
11. The FRAX.I.S. Study Group. Comparison of two treatment durations (6 days and 14 days) of a low
molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial
management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in
Ischaemic Syndrome). European Heart J 1999; 20:1553-1562.
12. Cannon, C. P. et al, for the OPUS-TIMI 16 Investigators. Oral glycoprotein IIb/IIIa inhibition with
orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;
13. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban or both for secondary
prevention after acute coronary syndromes. Circulation. 2001;103:1727-1733.
14. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S.,
Kleiman, J., Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left
CV - T. Campbell 20
ventricular dysfunction after myocardial infarction. (EPHESUS Study). N. Engl. J. Med. 2003;
15. Doughty, R.N., Whalley, G.A., Walsh, H.A., Gamble, G.D., Lopez-Sendon, J., Sharpe, N., on
behalf of the CAPRICORN Echo substudy investigators. Effects of carvedilol on left ventricular
remodelling after acute myocardial infact: The CAPRICORN Echo substudy. Circulation 2004;
109: 201 – 206.
16. Camm,AJ, Pratt, CM, Schwartz, PJ Al-Khalidi, HR Spyt, MJ Holroyde, MJ Karam, R
Sonnenblick,EH Brum, JMGand on Behalf of the AzimiLide post Infarct surVival Evaluation
(ALIVE) Investigators. Mortality in Patients After a Recent Myocardial Infarction: A Randomized,
Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification Circulation
2004; 109: 990-6.
CV - T. Campbell 21
CITATIONS OF FULL PAPERS as at March 2006
Source: Science Citation Index
Period Total Citation Count Self Citations
1973-1984 74 9
1985 37 2
1986 29 0
1987 69 6
1988 80 5
1989 121 2
1990 95 6
1991 110 9
1992 109 7
1993 84 14
1994 74 5
1995 53 0
1996 68 8
1997 66 2
1998 30 1
1999 16 1
2000 47 5
2001 34 2
2002 43 3
2003-March 2006 272 13
Totals 1511 100
Campbell, T.J. Cardiovasc Res 17, 344-352, 1983: 340 citations (including 11 self-citations).
ABSTRACTS & PAPERS IN NON PEER-REVIEWED JOURNALS
Not listed in the interests of space-can be provided if requested
CV - T. Campbell 22